Lead Product(s): Regdanvimab
Therapeutic Area: Infections and Infectious Diseases Product Name: CT-P59
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2021
Regdanvimab is a monoclonal antibody with activity against COVID-19. A monoclonal antibody is a type of protein that has been designed to attach to a specific structure (called an antigen).
Lead Product(s): NVX-COV2373,Matrix-M1
Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373
Highest Development Status: Phase III Product Type: Vaccine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration February 15, 2021
SK Bioscience will add significant production capacity under this new agreement. Novavax recently reported positive interim efficacy results for the NVX-CoV2373 in an ongoing Phase 3 trial in the U.K and is also currently conducting a Phase 3 trial in the U.S. and Mexico.